Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Articles
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Oncology
241 Articles Available
1
11
Can't find what you're looking for? Try our
advanced search
.
Enpoint
Lilly's CYRAMZA® Phase 3 RELAY Trial Met Primary Endpoint in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
PR-M03-19-NI-039
Approval
European Commission Approved Tecentriq/Avastin Combination Therapy for Lung Cancer
PAO-M03-19-NI-018
Oncology
Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference
PR-M03-19-NI-029
FDA Approval
NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer
PR-M03-19-NI-018
Research
Mallinckrodt Presents Data on Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting
PR-M03-19-NI-013
FDA
New Form of Herceptin Approved by U.S. FDA for Breast Cancer
PAO-M03-19-NI-010
Acquistion
Cancer Vaccine Company Snapped Up by Merck
PAO-M03-19-NI-002
Clinical Study
Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer
PR-M03-19-NI-012
Oncology
Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
PR-M03-19-NI-005
Clinical Trials
AIVITA Completes Treatment of First Patient in Phase 2 Ovarian Cancer Trial
PR-M02-19-NI-049
CAR-T
Will CAR-T Therapies be Covered by Medicare?
PAO-M02-19-NI-024
Generics
Roche Counters Generic Competition with New Cancer Treatments
PAO-M02-19-NI-022
Drug Development
Promising Treatment for Brain Cancer
PAO-M02-19-NI-019
Accelerated Approval
Merck’s Keytruda to Get Accelerated FDA Evaluation for Treatment of Head and Neck Cancer
PAO-M02-19-NI-015
Oncology
Bayer to Obtain Full Rights to Global Development and Commercialization of Oncology Compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)
PR-M02-19-NI-040
Immunotherapy
AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy
PR-M02-19-NI-031
Oncology
Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare's SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
PR-M02-19-NI-029
Immunotherapy
Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-202
PR-M02-19-NI-024
Collaboration
Antidote Therapeutics Announces Collaboration with National Cancer Institute to Develop ATI-1013, a Novel Nicotine-Binding Antibody
PR-M02-19-NI-019
Oncology
Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)
PR-M01-19-NI-089
Oncology
Lilly to Spend $8 Billion on Loxo Oncology
PAO-M01-19-NI-016
Oncology
Gene-Expression Profiling Raises Costs for Cancer Care without Improving Outcomes for Low-Risk Breast Cancer Patients, According to Researchers
PR-M01-19-NI-076
Oncology
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®
PR-M01-19-NI-067
Oncology
ImaginAb Enrolls First Patient in Phase II Clinical Trial
PR-M01-19-NI-066
1
11
»
